AML(acute myeloid leukemia)
Conditions
Interventions
None listed
Sponsors
Japan Adult Leukemia Study Group
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Age 16-79y at the time of initial diagnosis. (2) Untreated AML. AML are defined in accordance with the Acute myeloid leukemia (AML) and related neoplasms in WHO classification, 2016 edition. (3) ECOG performance status score:0-3 and sufficient hepatic, renal, and cardiac function satisfying the laboratory data. (4) Patients who have the standard anticancer drug treatments. (5) Patients who provided written informed consent for this study by themselves. (6) Patients who are under 20 years of age are required to give informed consent by legally acceptable representative.
Exclusion criteria
Exclusion criteria: (1)APL with PML-RARA, Myeloid sarcoma (2) Less than 30% of blast and meet the RAEB-t in the FAB classification. (3)Patients with complications including an activity double cancer, uncontrolled diabetes, and a serious infection.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Identification rate of patients with potentially actionable findings(PAF) by introduction of the clinical sequencing. | — |
Secondary
| Measure | Time frame |
|---|---|
| Identification rate of the clinically impactful findings (CIF). The average number of days required to return the genome analysis information to the doctor in charge. Identification rate of patients in which the genome cannot be analyzed and its causes. Identification rate of patients that germ cell sequence mutations were identified which are supposed to return the information report. | — |
Countries
Japan
Contacts
Public ContactHisayuki Yokoyama
Tohoku University Graduate School of Medicine Department of Hematology
Outcome results
None listed